- Home
- SBR vs GPCR Comparison
SBR vs GPCR Comparison
Compare SBR & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBR
- GPCR
- Stock Information
- Founded
- SBR 1982
- GPCR 2016
- Country
- SBR United States
- GPCR United States
- Employees
- SBR N/A
- GPCR N/A
- Industry
- SBR Oil & Gas Production
- GPCR
- Sector
- SBR Energy
- GPCR
- Exchange
- SBR Nasdaq
- GPCR Nasdaq
- Market Cap
- SBR 972.2M
- GPCR 1.1B
- IPO Year
- SBR N/A
- GPCR 2023
- Fundamental
- Price
- SBR $66.25
- GPCR $19.25
- Analyst Decision
- SBR
- GPCR Strong Buy
- Analyst Count
- SBR 0
- GPCR 7
- Target Price
- SBR N/A
- GPCR $76.17
- AVG Volume (30 Days)
- SBR 27.0K
- GPCR 740.5K
- Earning Date
- SBR 01-01-0001
- GPCR 08-07-2025
- Dividend Yield
- SBR 7.60%
- GPCR N/A
- EPS Growth
- SBR N/A
- GPCR N/A
- EPS
- SBR 5.34
- GPCR N/A
- Revenue
- SBR $81,761,891.00
- GPCR N/A
- Revenue This Year
- SBR N/A
- GPCR N/A
- Revenue Next Year
- SBR N/A
- GPCR N/A
- P/E Ratio
- SBR $12.32
- GPCR N/A
- Revenue Growth
- SBR N/A
- GPCR N/A
- 52 Week Low
- SBR $58.25
- GPCR $13.22
- 52 Week High
- SBR $70.20
- GPCR $45.37
- Technical
- Relative Strength Index (RSI)
- SBR 47.70
- GPCR 40.09
- Support Level
- SBR $65.35
- GPCR $18.94
- Resistance Level
- SBR $67.30
- GPCR $20.25
- Average True Range (ATR)
- SBR 0.92
- GPCR 0.93
- MACD
- SBR -0.08
- GPCR 0.05
- Stochastic Oscillator
- SBR 27.74
- GPCR 31.38
About SBR Sabine Royalty Trust
Sabine Royalty Trust is an express trust which is formed to receive Sabine Corporation's royalty and mineral interests, including landowner's royalties, overriding royalty interests, minerals production payments and any other similar, non-participatory interests, in certain Royalty Properties. The trusts producing and proved undeveloped oil and gas royalty properties are located in Florida, Louisiana, Mississippi, New Mexico, Oklahoma, and Texas.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.